Skip to main content
Top
Published in: BMC Pediatrics 1/2016

Open Access 01-12-2016 | Research article

Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children

Authors: Margery A. Connelly, Chisato Shimizu, Deborah A. Winegar, Irina Shalaurova, Ray Pourfarzib, James D. Otvos, John T. Kanegaye, Adriana H. Tremoulet, Jane C. Burns

Published in: BMC Pediatrics | Issue 1/2016

Login to get access

Abstract

Background

Glycosylation patterns of serum proteins, such as α1-acid glycoprotein, are modified during an acute phase reaction. The response of acute Kawasaki disease (KD) patients to IVIG treatment has been linked to sialic acid levels on native IgG, suggesting that protein glycosylation patterns vary during the immune response in acute KD. Additionally, the distribution and function of lipoprotein particles are altered during inflammation. Therefore, the aim of this study was to explore the potential for GlycA, a marker of protein glycosylation, and the lipoprotein particle profile to distinguish pediatric patients with acute KD from those with other febrile illnesses.

Methods

Nuclear magnetic resonance was used to quantify GlycA and lipoprotein particle classes and subclasses in pediatric subjects with acute KD (n = 75), post-treatment subacute (n = 36) and convalescent (n = 63) KD, as well as febrile controls (n = 48), and age-similar healthy controls (n = 48).

Results

GlycA was elevated in acute KD subjects compared to febrile controls with bacterial or viral infections, IVIG-treated subacute and convalescent KD subjects, and healthy children (P <0.0001). Acute KD subjects had increased total and small low density lipoprotein particle numbers (LDL-P) (P <0.0001) and decreased total high density lipoprotein particle number (HDL-P) (P <0.0001) compared to febrile controls. Consequently, the ratio of LDL-P to HDL-P was higher in acute KD subjects than all groups tested (P <0.0001). While GlycA, CRP, erythrocyte sedimentation rate, LDL-P and LDL-P/HDL-P ratio were able to distinguish patients with KD from those with other febrile illnesses (AUC = 0.789–0.884), the combinations of GlycA and LDL-P (AUC = 0.909) or GlycA and the LDL-P/HDL-P ratio (AUC = 0.910) were best at discerning KD in patients 6–10 days after illness onset.

Conclusions

High levels of GlycA confirm enhanced protein glycosylation as part of the acute phase response in KD patients. When combined with common laboratory tests and clinical characteristics, GlycA and NMR-measured lipoprotein particle parameters may be useful for distinguishing acute KD from bacterial or viral illnesses in pediatric patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54(3):271–6.PubMed Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54(3):271–6.PubMed
3.
go back to reference Suzuki A, Kamiya T, Kuwahara N, Ono Y, Kohata T, Takahashi O, et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol. 1986;7(1):3–9. doi:10.1007/BF02315475.CrossRefPubMed Suzuki A, Kamiya T, Kuwahara N, Ono Y, Kohata T, Takahashi O, et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol. 1986;7(1):3–9. doi:10.​1007/​BF02315475.CrossRefPubMed
6.
go back to reference Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. NEJM. 1991;324(23):1633–9. doi:10.1056/NEJM199106063242305.CrossRefPubMed Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. NEJM. 1991;324(23):1633–9. doi:10.​1056/​NEJM199106063242​305.CrossRefPubMed
7.
go back to reference Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circ. 2004;110(17):2747–71. doi:10.1161/01.CIR.0000145143.19711.78.CrossRef Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circ. 2004;110(17):2747–71. doi:10.​1161/​01.​CIR.​0000145143.​19711.​78.CrossRef
10.
go back to reference Akinkuolie AO, Glynn RJ, Ridker PM, Mora S. Protein glycan side-chains, rosuvastatin therapy, and incident vascular events: an anlysis from the JUPITER trial. Circ. 2014;130(S_2):A17731. Akinkuolie AO, Glynn RJ, Ridker PM, Mora S. Protein glycan side-chains, rosuvastatin therapy, and incident vascular events: an anlysis from the JUPITER trial. Circ. 2014;130(S_2):A17731.
11.
go back to reference Muhlestein JB, Mays H, Winegar D, Rollo J, Connelly M, Otvos J, Anderson J. GlycA and GlycB, novel NMR biomarkers of inflammation, strongly predict future cardiovascular events, but not the presence of coronary artery disease (CAD), among patients undergoing, coronary angiography: the Intermountain Heart Collaborative Study. JACC. 2014;63(12_S):61389. Muhlestein JB, Mays H, Winegar D, Rollo J, Connelly M, Otvos J, Anderson J. GlycA and GlycB, novel NMR biomarkers of inflammation, strongly predict future cardiovascular events, but not the presence of coronary artery disease (CAD), among patients undergoing, coronary angiography: the Intermountain Heart Collaborative Study. JACC. 2014;63(12_S):61389.
12.
go back to reference McGarrah R, Craig D, Haynes C, Dowdy ZE, Shah S, Kraus W. GlycA, a novel biomarker of systemic inflammation, improves cardiovascular risk prediction in a high-risk coronary catheterization cohort. JACC. 2015;65(10S):A1606.CrossRef McGarrah R, Craig D, Haynes C, Dowdy ZE, Shah S, Kraus W. GlycA, a novel biomarker of systemic inflammation, improves cardiovascular risk prediction in a high-risk coronary catheterization cohort. JACC. 2015;65(10S):A1606.CrossRef
14.
go back to reference Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. ATVB. 2015;35(6):1544–50. doi:10.1161/ATVBAHA.115.305635. Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. ATVB. 2015;35(6):1544–50. doi:10.​1161/​ATVBAHA.​115.​305635.
15.
go back to reference Connelly MA, Gruppen EG, Wolak-Dinsmore J, Matyus SP, Riphagen IJ, Shalaurova I, et al. GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study. Clin Chim Acta. 2015;452:10–7. doi:10.1016/j.cca.2015.11.001.CrossRefPubMed Connelly MA, Gruppen EG, Wolak-Dinsmore J, Matyus SP, Riphagen IJ, Shalaurova I, et al. GlycA, a marker of acute phase glycoproteins, and the risk of incident type 2 diabetes mellitus: PREVEND study. Clin Chim Acta. 2015;452:10–7. doi:10.​1016/​j.​cca.​2015.​11.​001.CrossRefPubMed
16.
go back to reference Ormseth MJ, Chung CP, Oeser AM, Connelly MA, Sokka T, Raggi P, et al. Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. Arthritis Res & Ther. 2015;17(1):117. doi:10.1186/s13075-015-0646-x.CrossRef Ormseth MJ, Chung CP, Oeser AM, Connelly MA, Sokka T, Raggi P, et al. Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis. Arthritis Res & Ther. 2015;17(1):117. doi:10.​1186/​s13075-015-0646-x.CrossRef
21.
24.
go back to reference Chung CP, Ormseth MJ, Oeser A, Solus JF, Connelly MA, Otvos JD, Stein CM. GlycA, a novel NMR marker of inflammation, is elevated in systemic lupus erythematosus. Lupus. 2016;25:296–300. Chung CP, Ormseth MJ, Oeser A, Solus JF, Connelly MA, Otvos JD, Stein CM. GlycA, a novel NMR marker of inflammation, is elevated in systemic lupus erythematosus. Lupus. 2016;25:296–300.
25.
go back to reference G HB, Rao VS, Kakkar VV. Friend Turns Foe: Transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response. Cholesterol. 2011:274629. doi:10.1155/2011/274629 G HB, Rao VS, Kakkar VV. Friend Turns Foe: Transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response. Cholesterol. 2011:274629. doi:10.​1155/​2011/​274629
Metadata
Title
Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki disease from other febrile illnesses in children
Authors
Margery A. Connelly
Chisato Shimizu
Deborah A. Winegar
Irina Shalaurova
Ray Pourfarzib
James D. Otvos
John T. Kanegaye
Adriana H. Tremoulet
Jane C. Burns
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2016
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-016-0688-5

Other articles of this Issue 1/2016

BMC Pediatrics 1/2016 Go to the issue